Compare · AKAN vs DFTX
AKAN vs DFTX
Side-by-side comparison of Akanda Corp. (AKAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.10B, about 2904.1x AKAN ($1.8M).
- DFTX has been more active in the news (7 items in the past 4 weeks vs 4 for AKAN).
- DFTX has more recent analyst coverage (7 ratings vs 0 for AKAN).
- Company
- Akanda Corp.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.8M
- $5.10B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 7
- Recent ratings
- 0
- 7
AKAN
Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Latest AKAN
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client
- SEC Form 6-K filed by Akanda Corp.
- Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
- SEC Form 6-K filed by Akanda Corp.
- Coloured Ties Capital Announces Proposed Share Consolidation
- SEC Form 6-K filed by Akanda Corp.
- From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes
- SEC Form 6-K filed by Akanda Corp.
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)